<code id='09138859A9'></code><style id='09138859A9'></style>
    • <acronym id='09138859A9'></acronym>
      <center id='09138859A9'><center id='09138859A9'><tfoot id='09138859A9'></tfoot></center><abbr id='09138859A9'><dir id='09138859A9'><tfoot id='09138859A9'></tfoot><noframes id='09138859A9'>

    • <optgroup id='09138859A9'><strike id='09138859A9'><sup id='09138859A9'></sup></strike><code id='09138859A9'></code></optgroup>
        1. <b id='09138859A9'><label id='09138859A9'><select id='09138859A9'><dt id='09138859A9'><span id='09138859A9'></span></dt></select></label></b><u id='09138859A9'></u>
          <i id='09138859A9'><strike id='09138859A9'><tt id='09138859A9'><pre id='09138859A9'></pre></tt></strike></i>

          Home / comprehensive / hotspot

          hotspot


          hotspot

          author:comprehensive    Page View:76277
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In